The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015
Abstract This study provides econometric evidence about the impact that new chemical entity (NCE) launches had on premature mortality from 17 diseases in 9 Middle Eastern and African countries during the period 2007–2015. The greater the relative number of NCEs for a disease launched in a country, the greater the subsequent relative decline in premature mortality from that disease, controlling for the average rate of mortality decline in each country and from each disease. An 8-year increase in the number of post-1992 NCEs ever launched is estimated to have reduced the number of years of potential life lost before age 75 (YPLL75) in 2015 by 9.5 %. This is approximately half of the 18.9 % reduction in YPLL75, and about one-third of the 29.7 % reduction in the premature mortality rate. In the absence of 8 previous years of NCE launches, 2.80 million additional YPLL before age 75 would have been lost in 2015. Expenditure on new drugs per life-year below age 75 gained in 2015 from the drugs was $US 834. According to the standards of the WHO’s Choosing Interventions that are cost–effective project, new drugs launched in the nine ME&A countries were very cost–effective overall.